Relationship between circulating levels of IFN-γ, IL-10, CXCL9 and CCL2 in pulmonary and extrapulmonary tuberculosis is dependent on disease severity

Scandinavian Journal of Immunology

Volumn 69, Issue 3, 2009, Pages 259-267

  Hasan, Z ^a,b   Jamil, B ^a   Khan, J ^a   Ali, R ^b   Khan, M A ^a   Nasir, N ^b   Yusuf, M S ^b   Jamil, S ^b   Irfan, M ^a   Hussain, R ^b  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b Department of Pathology and Microbiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; BLOOD LEVEL; CELLULAR IMMUNITY; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; ENDEMIC DISEASE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; SEROLOGY; VACCINATION;

ADULT; BCG VACCINE; CHEMOKINE CCL2; CHEMOKINE CXCL9; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; MYCOBACTERIUM TUBERCULOSIS; STATISTICS, NONPARAMETRIC; TUBERCULOSIS, PULMONARY;

EID: 60349098468     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02217.x     Document Type: Article

References (43)

1. Treatment of Tuberculosis. Guidelines for National Programmes, 3rd edn. World Health Organization, Geneva, Switzerland, 2003.
2. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res 2004 120 : 316 53.
3. Cagatay AA, Caliskan Y, Aksoz S et al. Extrapulmonary tuberculosis in immunocompetent adults. Scand J Infect Dis 2004 36 : 799 806.
4. Country Profile Pakistan. Global Tuberculosis Control. Global Tuberculosis Program, World Health Organization, Geneva, Switzerland, 2008.
5. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for IFN-γ in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993 178 : 2249 54.
6. Cooper AM, Magram J, Ferrante J, Orme I. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997 186 : 39 45.
7. Murray PJ, Young RA. Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect Immun 1999 67 : 3087 95.
8. Kindler V, Sappino AP, Grau GE, Piguet PF, Via LE, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989 56 : 731 40.
9. Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002 168 : 4620 7.
10. Saunder BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol 2007 85 : 103 11.
11. Collins HL, Kaufmann SHE. The many faces of host responses to tuberculosis. Immunol 2001 103 : 1 9.
12. Ulrichs T, Kosmiadi GA, Jörg S et al. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculosis. J Infect Dis 2005 192 : 89 97.
13. Algood HMS, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev 2003 14 : 467 77.
14. Peters W, Scott HM, Chambers HF, Flynn JL, Charo IF, Ernst JD. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2001 98 : 7958 63.
15. Scott HM, Flynn JL. Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Infect Immun 2002 70 : 5946 54.
16. Brice GT, Graber JL, Hoffman SL, Doolan DL. Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-gamma production and IFN-gamma-secreting cells. J Immunol Methods 2001 257 : 55 69.
17. Dlugovitzky D, Torres-Morales A, Rateni L et al. Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degrees of pulmonary involvement. FEMS Immunol Med Microbiol 1997 18 : 203 7.
18. Sahiratmadja E, Alisjahbana B, Buccheri S et al. Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gamma levels correlate with tuberculosis disease activity in adults. Tuberculosis 2007 87 : 312 21.
19. Morosini M, Meloni F, Bianco AM et al. The assessment of IFNγ and its regulatory cytokines in the plasma and bronchoalvelar lavage fluid of patients with active pulmonary tuberculosis. Int J Tuberc Lung Dis 2003 7 : 994 1000.
20. Vankayalapati R, Wizel B, Weis SE et al. Serum cytokine concentrations do not parallel Mycobacterium tuberculosis-induced cytokine production in patients with tuberculosis. Clin Infect Dis 2003 36 : 24 8.
21. Lee JS, Song CH, Lim JH et al. Monocyte chemotactic protein-1 production in patients with active pulmonary tuberculosis and tuberculous pleurisy. Inflamm Res 2003 52 : 297 304.
22. Yamada G, Shijubo N, Tkagi-Takahashi Y et al. Elevated levels of serum macrophage migration inhibitory factor in patients with pulmonary tuberculosis. Clin Immunol 2002 104 : 123 7.
23. Friedland JS, Hartley JC, Hartley CG, Shattock RJ, Griffin GE. Inhibition of ex vivo proinflammatory cytokine secretion in fatal Mycobacterium tuberculosis infection. Clin Exp Immunol 1995 100 : 233 8.
24. Alessandri AL, Souza AL, Oliveira SC, Macedo GC, Teixeira MM, Teixeira AL. Concentrations of CXCL8, CXCL9 and sTNFR1 in plasma of patients with pulmonary tuberculosis undergoing treatment. Inflamm Res 2006 55 : 528 33.
25. Kurashima K, Mukaida N, Fujimura M et al. Elevated chemokine levels in bronchalveolar lavage fluid of tuberculosis patients. Am J Respir Crit Care Med 1997 155 : 1474 7.
26. Mastroianni CM, Lancella L, Mengoni F et al. Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis. Clin Exp Immunol 1998 114 : 210 4.
27. Mohammed KA, Nasreen N, Ward MJ, Mubarak KK, Rodriguez-Panadero F, Antony VB. Mycobacterium-mediated chemokine expression in pleural mesothelial cells: role of C-C chemokines in tuberculous pleurisy. J Infect Dis 1998 178 : 1450 6.
28. Juffermans N, Verbon A, vn Deventer S, van Deutekom H, Speelman P, van der Poll T. Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Am J Resp Crit Care Med 1998 157 : 1328 31.
29. Verbon A, Juffermans N, Deventer S, Speelman P, Deutekom H, van der Poll T. Serum concentrations of cytokine in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 1999 115 : 110 3.
30. Sharma SK, Mitra DK, Balamurugan A, Pandey RM, Mehra NK. Cytokine polarization in miliary and pleural tuberculosis. J Clin Immunol 2002 22 : 345 52.
31. Jamil B, Shahid F, Hasan Z et al. Interferon γ:IL10 ratio defines the severity of disease in pulmonary and extra-pulmonary tuberculosis. Tuberculosis 2007 87 : 279 87.
32. Crofton J. Clinical Features of Tuberculosis. Crofton and Douglas Respiratory Diseases. London : Blackwell Scientific, 1990.
33. Hussain R, Hasan R, Khurshid M, Sturm AW, Ellner JJ, Dawood G. Pulmonary tuberculosis in a BCG vaccinated area: Relationship of disease severity with immunological and hematological parameters and drug resistance patterns. Southeast Asian J Trop Med Public Health 1996 27 : 257 62.
34. Hasan Z, Jamil B, Zaidi I, Zafar S, Khan AA, Hussain R. Elevated serum CCL2 concomitant with a reduced Mycobacterium-induced response leads to disease dissemination in leprosy. Scand J Immunol 2006 63 : 241 7.
35. Hasan Z, Zaidi I, Jamil B, Khan MA, Kanji A, Hussain R. Elevated ex vivo monocyte chemotactic protein-1 (CCL2) in pulmonary as compared with extra-pulmonary tuberculosis. BMC Immunol 2005 6 : 14.
36. Ebdrup L, Storgaard M, Jensen-Fangel S, Obel N. Ten years of extrapulmonary tuberculosis in a Danish university clinic. Scand J Infect Dis 2003 35 : 244 6.
37. Hussain R, Hasan R, Khurshid M, Sturm AW, Ellner JJ, Dawood G. Pulmonary tuberculosis in a BCG vaccinated area: relationship of disease severity with immunological and hematological parameters and drug resistance patterns. Southeast Asian J Trop Public Health 1996 27 : 257 62.
38. Kasahara K, Sato I, Ogura K, Takeuchi H, Kobayashi K, Adachi M. Expression of chemokines and induction of rapid cell death in human blood neutrophils by Mycobacterium tuberculosis. J Infect Dis 1998 178 : 127 37.
39. Hussain SF, Irfan M, Abbasi M et al. Clinical characteristics of 110 miliary tuberculosis patients from a low HIV prevalence country. Int J Tuberc Lung Dis 2004 8 : 493 9.
40. Kasahara K, Tobe T, Tomita M et al. Selective expression of monocyte chemotactic and activating factor/monocyte chemotactic protein 1 in human blood monocytes by Mycobacterium tuberculosis. J Infect Dis 1994 170 : 1238 47.
41. Abramo C, Meijgaarden K, Garcia D et al. Monokine induced by interferon gamma and IFN-gamma response to a fusion protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian tuberculosis patients. Microbes Infect 2006 8 : 45 51.
42. Dlugovitzky D, Bay ML, Rateni L, Fiorenza G, Vietti L, Farroni MA. Influence of disease severity on nitrite and cytokine production by peripheral blood mononuclear cells (PBMC) from patients with pulmonary tuberculosis (TB). Clin Exp Immunol 2000 122 : 343 9.
43. Olobo JO, Geletu M, Demissie A et al. Circulating TNF-α, TGF-β and IL-10 in tuberculosis patients and healthy contacts. Scand J Immunol 2000 53 : 85 91.